Incyte didn’t show it would suffer real harm if Sun entered the market, especially since Incyte’s version of the alopecia drug isn’t expected to be available until years after US Patent No. 9,662,335 expires in December 2026, Chief Judge Kimberly A. Moore wrote in an opinion issued Wednesday by the US Court of Appeals for the Federal Circuit.
The three-judge panel lifted the injunction in ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.